Aldéric Fraslin - Concepedia

Author

Aldéric Fraslin

Also Known As

A. Fraslin, A.M. Fraslin, Alderic M. Fraslin, Aldéric FRASLIN, Aldéric Fraslin, Aldéric M. Fraslin, Aldéric Masoandro Fraslin

Publications

471

Citations

H-Index

Concepts

All Affiliations

Aldéric Fraslin is an author at Institut Gustave Roussy specializing in medicine, oncology, and cancer research.

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	260
2	Health Sciences	1	1	214
3	Surgical Oncology	1	1	46
4	Cancer Therapeutics	1	1	214
5	Head And Neck Cancer	1	1	214

Aldéric Fraslin

Publications

465

Citations

H-Index

Page 1

	Year	Citations
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial J. Guigay, Anne Aupérin, Jérôme Fayette, The Lancet Oncology Gortec 2014-01 TpextremeNeoadjuvant TherapyMedicineCisplatin Versus PlatinumHead And Neck Cancer	2021	214
Impact of COVID-19 on healthcare organisation and cancer outcomes A. Bardet, Aldéric Fraslin, J. Marghadi, European Journal of Cancer	2021	183
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial Axel Le Cesne, Jean‐Yves Blay, Didier Cupissol, Annals of Oncology MedicineSurgerySurgical OncologyOncology	2021	46
Cetuximab, Docetaxel and Cisplatin as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results of the GORTEC 2014-01 TPExtreme Randomized Trial J. Guigay, Anne Aupérin, Jérôme Fayette, SSRN Electronic Journal	2020	12
Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life Thierry Lebrét, Julia Bonastre, Aldéric Fraslin, BMJ Open	2023	10

Page 1